Maven cuts IVF costs for employers
Maven Clinic
This is how Maven turns fertility from an expensive claims category into a utilization management product. If Maven can move a meaningful share of members to lower cost paths first, through cycle tracking, nutrition support, medication guidance, and specialist coaching, it gives employers a concrete reason to buy Maven Managed Benefits, not just for access, but to avoid IVF cycles that can cost about $15,000 each and carry rapidly rising drug spend.
-
Maven sits between the employer and a fragmented fertility journey. Members use one app to message care advocates, book OB-GYN or fertility consults, get reimbursement through Maven Wallet, and access a network of 475+ fertility clinics. That lets Maven influence decisions before members reach the most expensive intervention.
-
This is a clear point of contrast with Progyny and Kindbody. Progyny is more exposed to IVF treatment spend and operates at about 20% gross margin because of pass through costs, while Kindbody owns clinics and makes more money when procedures happen. Maven instead is paid for coordination and savings, which fits employers that want tighter cost control.
-
The timing matters because IVF inputs are getting more expensive, not less. IVF medication list prices rose 84% from 2014 to 2024, versus 37% for prescription drugs overall. As more big employers add fertility coverage, the vendor that can show fewer unnecessary cycles and lower pharmacy spend has the strongest ROI story.
Going forward, fertility benefits will split between companies that make money from more treatment and companies that make money from better triage. Maven is building toward the second model. That should make its full stack administrator role more valuable to employers and health plans that want one vendor to manage access, outcomes, and total cost together.